Caribou lays off 32% of staff, cuts lupus program
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid a bleak biotech market. Caribou said Thursday...
View ArticleGilead Q1 earnings: Strong HIV business balances out low Covid and cancer...
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year. The Foster City ...
View ArticleMerck KGaA closes in on SpringWorks deal at $3.5B price point
Merck KGaA said Thursday that its late-stage discussions to buy the rare cancer biotech SpringWorks Therapeutics have landed on a likely price of $47 per share. That would put the value of the pending...
View ArticlePaul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up...
When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing the job for two to three years. Galapagos — a company he helped found ...
View ArticleAbbVie Q1 earnings: Immunology still a powerhouse as Skyrizi, Rinvoq hit $5B...
One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues to start 2025. AbbVie’s overall revenues for...
View ArticleMerck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on...
Plus, news about Verastem Oncology, Oryzon Genomics, Azitra, Vivoryon Therapeutics and Akeso: Merck cuts several Phase 2 programs: The company stopped work on two mid-stage programs testing...
View ArticleAlis Biosciences to press struggling biotechs during downturn
The horde of zombie biotechs lurching ahead and barely surviving has reached a crisis level for some investors. Now there’s a new investment fund targeting these companies. Nicholas Johnston, a...
View ArticleALX Oncology reports Phase 2 failures for CD47 drug combo with Keytruda
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump. The company said Friday that two trials testing different combinations of its CD47-targeting drug failed to meet their ...
View ArticleAkeso reveals survival data for Keytruda-beating cancer drug
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes will top Merck's megablockbuster PD-1 drug. As part of the approval, the...
View ArticleRFK Jr. touts program testing ways to pay for sickle cell care
CHARLESTON, SC — HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to improve access to and lower costs for gene therapies for ...
View ArticleCompounding pharmacies dealt blow in semaglutide shortage case
Novo Nordisk scored a major win in its wide-ranging legal fight to keep compounders from making copies of its obesity drug semaglutide. A federal district court in Texas on Thursday denied a request...
View ArticleAmgen invests $900M to expand Ohio biomanufacturing
Amgen is the latest in a series of biopharma companies to announce a massive new US-based investment in manufacturing in response to the Trump administration's call to bring pharma manufacturing to the...
View ArticleAbbVie eyes $10B US expansion amid sector-specific tariff threat
AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of pharmaceutical-specific tariffs looms. AbbVie announced plans in its first-quarter...
View ArticleFDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
FDA Commissioner Marty Makary is ramping up his public presence, recently sitting for an interview with Megyn Kelly and participating in an HHS event on removing some dyes from the American food...
View ArticleEarnings season is upon us; Makary on rare disease; Startup is first to...
Welcome back to Endpoints Weekly! Our team of reporters covered first-quarter earnings results from a handful of companies this week. See below for pharma executives’ comments on tariff exposure,...
View ArticleJ&J reports durability data for bladder cancer 'pretzel' drug
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the latest data cut from a registrational trial....
View Article#AACR25: Revolution’s KRAS drug shows potential in early cut of lung cancer data
CHICAGO — An experimental KRAS G12D drug from Revolution Medicines made waves last year as a potential treatment for pancreatic cancer. On Sunday, new results from an early data readout showed it works...
View Article#AACR25: Keytruda around head and neck cancer surgery cuts chance of disease...
CHICAGO — Merck’s widely used cancer drug Keytruda could soon be getting another indication, this time for use before and after surgery for head and neck cancer. On Sunday, data presented from the...
View Article#AACR25: GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer
GSK’s Jemperli has maintained its outstanding efficacy among patients with a particular form of rectal cancer. Every one of 49 patients with mismatch repair deficient (MMRd) rectal tumors in a...
View ArticleExclusive: Axiom raises $15M to build AI models for drug toxicity
Brandon White started his career like a Silicon Valley stereotype — as a 20-year-old who skipped college to join Uber’s machine learning team in 2014. But White soon found himself unhappy and...
View Article